- Home
- JXG vs RDHL Comparison
JXG vs RDHL Comparison
Compare JXG & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JXG
- RDHL
- Stock Information
- Founded
- JXG N/A
- RDHL 2009
- Country
- JXG China
- RDHL Israel
- Employees
- JXG N/A
- RDHL N/A
- Industry
- JXG
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- JXG
- RDHL Health Care
- Exchange
- JXG Nasdaq
- RDHL Nasdaq
- Market Cap
- JXG 4.7M
- RDHL 3.9M
- IPO Year
- JXG N/A
- RDHL N/A
- Fundamental
- Price
- JXG $0.94
- RDHL $1.42
- Analyst Decision
- JXG
- RDHL
- Analyst Count
- JXG 0
- RDHL 0
- Target Price
- JXG N/A
- RDHL N/A
- AVG Volume (30 Days)
- JXG 118.3K
- RDHL 95.7K
- Earning Date
- JXG 05-15-2025
- RDHL 09-05-2025
- Dividend Yield
- JXG N/A
- RDHL N/A
- EPS Growth
- JXG N/A
- RDHL N/A
- EPS
- JXG 0.86
- RDHL N/A
- Revenue
- JXG $49,840,288.00
- RDHL $9,550,000.00
- Revenue This Year
- JXG N/A
- RDHL $381.91
- Revenue Next Year
- JXG N/A
- RDHL N/A
- P/E Ratio
- JXG $1.06
- RDHL N/A
- Revenue Growth
- JXG 56.53
- RDHL 157.62
- 52 Week Low
- JXG $0.55
- RDHL $1.06
- 52 Week High
- JXG $8.40
- RDHL $12.50
- Technical
- Relative Strength Index (RSI)
- JXG 37.93
- RDHL 50.29
- Support Level
- JXG $0.85
- RDHL $1.22
- Resistance Level
- JXG $1.04
- RDHL $1.49
- Average True Range (ATR)
- JXG 0.08
- RDHL 0.08
- MACD
- JXG 0.01
- RDHL 0.03
- Stochastic Oscillator
- JXG 39.33
- RDHL 72.22
About JXG JX Luxventure Limited Common Stock
JX Luxventure Group Inc is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Tourism products, Technology, and Cross board merchandise The majority of the group revenue is generated from Tourism products.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.